Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA.
Hosted on MSN
Expanding the Use of Targeted Therapy Pluvicto: New FDA Approval Brings Hope for Advanced Prostate Cancer
For men living with advanced prostate cancer and their loved ones, the road is often filled with difficult decisions and limited options. However, a new Food and Drug Administration (FDA) approval has ...
Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...
Pocenbrodib is being tested alone and with Zytiga, Lynparza, or Pluvicto in metastatic castration-resistant prostate cancer patients. The trial aims to address resistance to androgen receptor-targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results